Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of enfortumab vedotin in previously treated Chinese patients with advanced or metastatic urothelial carcinoma
CTR20210922Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin in transitional cell carcinoma (TCC), sponsored by Astellas Pharma. Started Aug 2021; status: completed.
02
Drugs
enfortumab vedotin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20210922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210922.